Related Experiment Video
Updated: Oct 11, 2025

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Misregulation of the expression and activity of DNA methyltransferases in cancer
Isaiah K Mensah1, Allison B Norvil2, Lama AlAbdi3
1Department of Biochemistry, Purdue University, West Lafayette, IN 47907, USA.
Abstract:
In mammals, DNA methyltransferases DNMT1 and DNMT3's (A, B and L) deposit and maintain DNA methylation in dividing and nondividing cells. Although these enzymes have an unremarkable DNA sequence specificity (CpG), their regional specificity is regulated by interactions with various protein factors, chromatin modifiers, and post-translational modifications of histones. Changes in the DNMT expression or interacting partners affect DNA methylation patterns. Consequently, the acquired gene expression may increase the proliferative potential of cells, often concomitant with loss of cell identity as found in cancer. Aberrant DNA methylation, including hypermethylation and hypomethylation at various genomic regions, therefore, is a hallmark of most cancers. Additionally, somatic mutations in DNMTs that affect catalytic activity were mapped in Acute Myeloid Leukemia cancer cells. Despite being very effective in some cancers, the clinically approved DNMT inhibitors lack specificity, which could result in a wide range of deleterious effects. Elucidating distinct molecular mechanisms of DNMTs will facilitate the discovery of alternative cancer therapeutic targets. This review is focused on: (i) the structure and characteristics of DNMTs, (ii) the prevalence of mutations and abnormal expression of DNMTs in cancer, (iii) factors that mediate their abnormal expression and (iv) the effect of anomalous DNMT-complexes in cancer.
Insights
DNA methyltransferases (DNMTs) regulate DNA methylation. Aberrant DNMT activity and expression are hallmarks of cancer, driving uncontrolled cell proliferation and loss of identity.
Area of Science:
- Epigenetics
- Molecular Biology
- Cancer Biology
Background:
- DNA methyltransferases (DNMTs) are crucial for establishing and maintaining DNA methylation patterns in mammals.
- DNMTs exhibit regional specificity through interactions with protein factors and chromatin modifications.
- Altered DNMT expression or interactions lead to aberrant DNA methylation, a hallmark of cancer.
Purpose of the Study:
- To review the structure, characteristics, and functions of DNMTs.
- To examine the prevalence of DNMT mutations and abnormal expression in various cancers.
- To explore factors mediating DNMT dysregulation and their impact on cancer development.
Main Methods:
- Literature review focusing on DNMT structure, function, and cancer relevance.
- Analysis of studies detailing DNMT mutations and expression patterns in cancer.
- Synthesis of research on protein interactions and epigenetic modifications affecting DNMTs.
Main Results:
- DNMTs (DNMT1, DNMT3A, DNMT3B, DNMT3L) play key roles in DNA methylation.
- Aberrant DNA methylation (hyper- and hypomethylation) is prevalent in cancer, linked to increased cell proliferation and identity loss.
- Somatic mutations in DNMTs are observed in cancers like Acute Myeloid Leukemia.
- Existing DNMT inhibitors lack specificity, causing side effects.
Conclusions:
- Understanding DNMT mechanisms is vital for cancer therapy.
- Elucidating DNMTs' molecular roles can identify novel therapeutic targets.
- Targeting DNMT complexes offers potential for more specific cancer treatments.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Abnormal Proliferation
MicroRNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Master Transcription Regulators

